Global NGS-Based RNA-Sequencing Market

Transcriptomics/RNA analysis is a study of the transcriptome under specific circumstances, environment, or in a specific cell using high-throughput methods. The main types of products in the RNA analysis/ transcriptomics market are reagents/consumables, instruments, and software. It is implemented in various areas including clinical diagnostics, drug discovery, toxicogenomics, comparative transcriptomics, and RNA interference. Major technology involved in RNA analysis/ transcriptomics are microarrays, sequencing, polymerase chain reaction RNA interference. RNA analysis is used in clinical diagnosis to detect different RNA species, and pathogen RNA splice variants among others useful in the diagnosis of diseases. The RNA analysis/ transcriptomics market research report is one of a series of new reports from The Business Research Company that provides RNA analysis/ transcriptomics market statistics, including RNA analysis/ transcriptomics industry global market size, regional shares, competitors with a RNA analysis/ transcriptomics market share, detailed RNA analysis/ transcriptomics market segments, market trends and opportunities, and any further data you may need to thrive in the RNA analysis/ transcriptomics industry. This RNA analysis/ transcriptomics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global rna analysis/ transcriptomics market size grew from $5.96 billion in 2022 to $6.76 billion in 2023 at a compound annual growth rate (CAGR) of 13.4%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The rna analysis/ transcriptomics market size is expected to grow to $11.33 billion in 2027 at a CAGR of 13.8%. The increasing demand for personalized medicine is expected to drive the growth of the RNA analysis/ transcriptomics market in the coming years. Personalized medicine refers to the customizing of medical treatment to each patient's unique characteristics. If scientists can implement the necessary practices and processes for personalized clinical care, RNA-Seq will be well-positioned to handle the massive clinical workload. According to the Personalized Medicine Report 2020 published by the Personalized Medicine Coalition (PMC), the number of personalized medicines in the market more than doubled between 2016 and 2020 in the USA. Therefore, the growing demand for personalized medicines propels the growth of the RNA analysis market. Technological advancements and innovations in RNA analysis are an emerging trend in the RNA analysis/ transcriptomics market. Technologies such as next-generation sequencing (NGS) and RNA interference (RNAi) improved precision and accuracy, which help researchers analyze the transcriptional activity. For instance, Next-generation sequencing developed by Illumina is successfully used in fragmenting DNA/RNA into multiple pieces, adding adapters, sequencing the libraries, and reassembling them to form a genomic sequence. In October 2020, 10x Genomics, a startup based in the USA acquired Cartana for an amount of $41.2 million. The acquisition of Cartana is expected to strengthen its approach to developing technologically advanced products. Cartana is a Sweden-based biotechnology player involved in developing in situ RNA analysis technology. Major players in the RNA analysis/ transcriptomics market are Affymetrix Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., GE Healthcare, Illumina Inc., Qiagen N.V., F. Hoffmann-La Roche Ltd., Sigma-Aldrich Corporation, Thermo Fisher Scientific Inc., Fluidigm Corporation, Promega Corporation, and Biomereiux SA. North America was the largest region in the RNA analysis/transcriptomics market in 2022. This region is expected to be the fastest-growing region in the forecast period. The regions covered in the RNA analysis/ transcriptomics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the RNA analysis/ transcriptomics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The RNA analysis/ transcriptomics market includes revenues earned by entities by providing services such as Whole-Genome Sequencing, Whole-Exome Sequencing, Targeted Sequencing, Microarray Analysis, Sanger Sequencing services. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced.It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global rna analysis or transcriptomics market is segmented - 1) By Product: Reagents/Consumables, Instruments, Software 2) By Technology, Microarrays, Sequencing, Polymerase Chain Reaction RNA Interference 3) By Application: Clinical Diagnostics, Drug Discovery, Toxicogenomics, Comparative Transcriptomics, RNA Interference

Antisense therapy refers to the selective, sequence-specific suppression of gene expression by single-stranded DNA oligonucleotides. Contrarily, RNA interference (RNAi) is activated by double-stranded RNA (dsRNA) and results in the sequence-specific mRNA degradation of single-stranded target RNAs. The main technologies of antisense & RNAi therapeutics are RNA interference and antisense RNA. RNA interference is a conserved biological response to double-stranded RNA that mediates resistance to both endogenous parasitic and exogenous pathogenic nucleic acids and regulates protein-coding gene expression. The various route of administration includes pulmonary delivery, intravenous injections, intra-dermal injections, intraperitoneal injections, topical delivery, and other delivery methods that are used for the indication of oncology, cardiovascular diseases (CVDs), respiratory disorders, neurological disorders, infectious diseases, other. The antisense & RNAi therapeutics market research report is one of a series of new reports from The Business Research Company that provides antisense & RNAi therapeutics market statistics, including antisense & RNAi therapeutics industry global market size, regional shares, competitors with antisense & RNAi therapeutics market share, detailed antisense & RNAi therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the antisense & RNAi therapeutics industry. This antisense & RNAi therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global antisense & rnai therapeutics market grew from $1.42 billion in 2022 to $1.54 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The antisense & rnai therapeutics market is expected to grow from $2.42 billion in 2027 at a CAGR of 12.0%. The rising prevalence of coronary artery diseases, neurodegenerative disorders, and infectious diseases is projected to contribute to the demand for the antisense & RNAi therapeutics market. Gene suppression approaches including RNA interference and antisense oligonucleotides are used for the treatment of various neurodegenerative conditions by repairing mutant genes. According to the National Institute of Environmental Health Sciences, Alzheimer’s disease and Parkinson’s disease are the most common neurodegenerative diseases affecting millions of people globally. In the USA, around 930,000 people had Parkinson’s disease by the end of 2020. Furthermore, according to the World Health Organization (WHO), infectious diseases are a major concern and dominated the WHO’s list of health threats ranging from various climate change issues to inadequate healthcare facilities. Hence, the growing prevalence of several neurodegenerative diseases and infectious diseases is expected to drive the growth of the antisense & RNAi therapeutics market. The high cost of RNA interference-based drugs is expected to act as a major restraint on the growth of the antisense & RNAi therapeutics market in the future. For instance, according to Future Medicine, the price of Onpattro is approximately $450,000 per year. Onpattro (patisaran) is the RNA interference-based drug used for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. Stringent regulations, a long product approval process, high development cost, and a comparably small number of patients are a few factors leading to the high cost of RNA interference drugs, which is expected to hinder the antisense & RNAi therapeutics market growth in upcoming years. Major companies operating in the antisense & RNAi therapeutics market are undertaking strategic initiatives such as collaborations and partnerships for product innovation to sustain in the increasingly competitive market, companies are developing innovative products as well as sharing skills and expertise with other companies. While companies have long collaborated as well as with academic and research institutions in this market by way of partnerships, and in or out-licensing deals. This trend has been increasing over recent years. For instance, in August 2020, Blackstone Life Sciences, a global investment company, and Alnylam Pharmaceuticals, Inc., an RNAi therapeutics company, announced the closing of a $2 billion strategic financing collaboration to accelerate the advancement and development of RNAi therapeutics. Under the agreement, Alnylam Pharmaceuticals, Inc. will receive $150 million from Blackstone Life Sciences for the development of vutrisiran and ALN-AGT, Alnylam’s cardiometabolic disease programs. In 2020, Aro Biotherapeutics Company has announced a licensing and collaboration agreement with Ionis Pharmaceuticals, Inc., the market leader in RNA-targeted therapeutics, under which Ionis will use Aro's CENTYRINTM technology to develop targeted cell- and tissue-specific delivery of antisense oligonucleotides (ASOs). In December 2021, AstraZeneca PLC., a UK-based pharmaceutical and biotechnology company, announced a strategic partnership with Ionis Pharmaceuticals, Inc., a US-based biopharmaceutical company pioneering in the discovery and development of RNA-based therapeutics and drugs. Under this strategic partnership, Eplontersen will be developed and commercialized by the two businesses together in the US and by AstraZeneca in all other regions outside of Latin America. Major players in the antisense & RNAi therapeutics market are Alnylam Pharmaceuticals, Benitec Biopharma Ltd., Gene Signal, GlaxoSmithKline PLC., Ionis Pharmaceuticals, Marina Biosciences, Quark Pharmaceuticals, Sanofi S.A, Acuitas Therapeutics and Antisense Therapeutics Ltd. North America was the largest region in the antisense & RNAi therapeutics market in 2022. The regions covered in the global antisense & RNAi therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the global antisense & RNAi therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The antisense and RNAi therapeutics market includes revenues earned by entities by regulating gene expression at multiple levels, such as at replication, transcription, and translation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values – that is, they are revenues generated by organizations in the specified geography within the specified market, irrespective of where they are produced.It does not include revenues from resales either further along the supply chain or as part of other products. The global antisense & rnai therapeutics market is segmented - 1) By Technology: RNA Interference, Antisense RNA 2) By Route of Administration: Pulmonary Delivery, Intravenous Injections, Intra-dermal Injections, Intraperitoneal Injections, Topical Delivery, Other Delivery Methods 3) By Indication: Oncology, Cardiovascular Diseases (CVDs), Respiratory Disorders, Neurological Disorders, Infectious Diseases, Other Indications

Next-generation sequencing is a sequencing technology that offers ultra-high throughput, scalability, and speed. The technology is used to determine the genetic variation associated with diseases or other biological phenomena. The main products in the next-generation sequencing market are NextSeq systems, MiniSeq systems, NovaSeq systems, iSeq 100 systems, ion PGM Systems, Ion Proton systems, ion GeneStudio S5 systems, PacBio RS II Systems, sequel systems, and others. The MiniSeq system merges load-and-go operation with an intuitive user interface for a fast, easy NGS workflow. The MiniSeq System integrates clonal amplification, sequencing through synthesis, and base calling into a single benchtop instrument, preventing the requirement for additional equipment. The various technologies in next-generation sequencing are sequencing by synthesis, ion semiconductor sequencing, single-molecule real-time sequencing, nanopore sequencing, and other sequencing technologies that are used in diagnostics, drug discovery, and other applications. The next-generation sequencing market research report is one of a series of new reports from The Business Research Company that provides next-generation sequencing market statistics, including next-generation sequencing industry global market size, regional shares, competitors with a next-generation sequencing market share, detailed next-generation sequencing market segments, market trends and opportunities, and any further data you may need to thrive in the next-generation sequencing industry. This next-generation sequencing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global next generation sequencing market size will grow from $9.22 billion in 2022 to $10.44 billion in 2023 at a compound annual growth rate (CAGR) of 13.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global next generation sequencing market size is expected to grow to $17.32 billion in 2027 at a CAGR of 13.5%. The growing number of cases with chronic conditions such as cancer, AIDS, and thalassemia contributed to the growth of the next-generation sequencing market. Chronic illnesses and disorders are on the rise around the world, an aging population and shifts in social behavior lead to a gradual increase in these widespread and expensive long-term medical issues. Next-generation sequencing (NGS) is a versatile development tool utilized by researchers and clinicians across various cancer studies to recognize biomarkers that give guidance on treatments. The prevalence of chronic diseases is also expected to increase significantly, according to the World Health Organization. Hence, the increase in the number of chronic disease cases will increase the requirement for NGS sequencing and boosts revenues for the next-generation sequencing market. The high cost associated with next-generation sequencing technologies is a key factor hampering the growth of the next-generation sequencing market. The next-generation sequencing market is facing challenges as many people find it difficult to afford the test due to the high cost. Consumables used for sequencing are the costliest portion of testing (68–72% of total cost) as machinery prices are higher in instances of rare disease. According to a review published on economic evaluations of exome and genome sequencing, the cost of next-generation genome sequencing ranges from $1906 to $24,810 for a single test. Therefore, the high cost of next-generation sequencing is anticipated to restrict market growth over the forecast period. Technological advances are shaping the next-generation sequencing market. Major companies operating in the sequencing industry are focusing on developing technologically advanced solutions for next-generation sequencing. For instance, in 2020, Thermo Fisher Scientific introduced hematology-oncology assays for the Ion Torrent Genexus System, which authorize simultaneous analysis of DNA mutations and RNA fusion transcripts in myeloid samples in a single day and also enabled further in which turnaround times for next-generation sequencing (NGS) results could be reduced to less than 24 hours. It also offers researchers the ability to profile 40 DNA targets and 29 fusion driver genes, authorizing observing more than 600 fusion isotypes to recognize biomarkers associated with myeloproliferative neoplasm, acute myeloid leukemia. Major players in the next-generation sequencing market are Illumina Inc., Thermo Fisher Scientific Inc., BGI Group, Agilent Technologies Inc., Qiagen N.V., Hoffmann-La Roche AG, Eurofins Scientific, Oxford Nanopore Technologies, Pacific Biosciences, and 10x Genomics. North America was the largest region in the next-generation sequencing market in 2022. Asia-Pacific was the second largest region in the global next-generation sequencing market. The regions covered in the global next-generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the next-generation sequencing market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA. The next-generation sequencing market consits of sales of genetic sequencing equipment with advanced features and technologies such as ion semiconductor sequencing, nano-pore sequencing, single-molecule real-time sequencing, and other technologies that are used for next generation sequencing. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global next generation sequencing market is segmented - 1) By Product: NextSeq Systems, MiniSeq Systems, NovaSeq Systems, iSeq 100 Systems, Ion PGM Systems, Ion Proton Systems, Ion GeneStudio S5 Systems, PacBio RS II Systems, Sequel Systems, Other Products 2) By Technology: Sequencing by Synthesis, Ion Semiconductor Sequencing, Single-molecule Real-time Sequencing, Nanopore Sequencing, Other Sequencing Technologies 3) By Application: Diagnostics, Drug Discovery, Other Applications

Biosimilar hormones refer to the hormones included in the product that are chemically identical to those produced by your body. In fact, it's possible that the hormones in bioidentical drugs are identical to those used in conventional hormone therapy. They are used to treat people whose hormone levels are low or out of whack. The main types of biosimilar hormones are teriparatide biosimilars, follitropin alfa biosimilars, insulin biosimilars, somatropin biosimilars and others. Teriparatide is a parathyroid hormone recombinant (PTH). Teriparatide is similar to a component of human PTH, and when taken regularly, it stimulates osteoblasts more than osteoclasts, increasing bone mass. The different applications include research and biotechnology, diagnostics, biocatalysts, therapeutics, and others and are distributed through various channels such as hospital and retail pharmacies, online pharmacies or e-pharmacy, and specialty clinics. The biosimilar hormones market research report is one of a series of new reports from The Business Research Company that provides biosimilar hormones market statistics, including biosimilar hormones industry global market size, regional shares, competitors with a biosimilar hormones market share, detailed biosimilar hormones market segments, market trends and opportunities, and any further data you may need to thrive in the biosimilar hormones industry. This biosimilar hormones market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global biosimilar hormones market grew from $2.31 billion in 2022 to $3.03 billion in 2023 at a compound annual growth rate (CAGR) of 31.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The biosimilar hormones market is expected to grow from $7.68 billion in 2027 at a CAGR of 26.2%. The prevalence of deficiencies in growth hormones and metabolic hormones contributes to the market. The treatments required for hormone-related conditions are evolving over the years, and the prevalence of hormonal deficiencies is generating higher demand for the hormone biosimilars market. For instance, in January 2022, according to the British Medical Journal, a UK-based peer-reviewed medical trade journal, the prevalence of GH deficiency (GHD) in children is thought to range from 1 in 3500 to 1 in 10000 across the globe. Also, in June 2022, according to a Medscape report, about 6,000 adults are expected to be diagnosed with growth hormone (GH) deficiency in the USA. The growing need to treat patients with prevailing hormonal deficiencies drives the biosimilar hormones market. Stringent regulations imposed on the approval of hormone biosimilars limit the growth of the biosimilar hormones market. Biosimilars are approved on the same standard of pharmaceutical quality, efficacy, and safety that apply to all biologics approved in the European Union. There should be a similarity between the biologics and biosimilars, and as the process of manufacturing differs, the approval process becomes expensive and likely hinders the growth of the biosimilar hormones market. Key players operating in the biosimilar hormones market are undertaking various strategic initiatives such as new product launches in untapped regions to make the drug accessible to a large population. The companies are focusing on launching their products in various locations to boost sales and maximise profits. For instance, in February 2022, Alvotech Holdings S.A., a Luxembourg-based biopharmaceutical company specialising in the development of biosimilar medicines, announced partnerships with Fuji Pharma Co. Ltd., a Japan based pharmaceutical company, to develop biosimilar drug candidates in Japan. Through this partnership, both companies have decided to add new elements to their strategic alliance for the creation and marketing of biosimilar medicines in Japan. Major players in the biosimilar hormones market are Teva Pharmaceutical, Gedeon Richter, Intas Pharmaceuticals, Biocon, Mylan, Sanofi, Sandoz (Novartis), LG Life Sciences, Ferring Pharmaceuticals, and GC Pharma. North America was the largest region in the biosimilar hormones market in 2022. The regions covered in the global biosimilar hormones market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the biosimilar hormones market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The biosimilar hormones market consists of sales of estrace, estradil, and estring. Values in this market are "factory gate values," that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global biosimilar hormones market is segmented - 1) By Type: Teriparatide Biosimilars, Follitropin Alfa Biosimilars, Insulin Biosimilars, Somatropin Biosimilars, Other Types 2) By Application: Research & Biotechnology, Diagnostics, Biocatalysts, Therapeutics, Other Applications 3) By Distribution Channel: Hospital And Retail Pharmacy, Online Pharmacy/e-pharmacy, Specialty Clinics

Anti-hypertensive drugs refer to a group of medications used to treat high blood pressure (high blood pressure). The goal of antihypertensive therapy is to prevent the negative effects of high blood pressure, such as myocardial infarction and stroke. The main therapeutics of anti-hypertensive drugs are diuretics, angiotensin receptor blockers (ARBs), angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, alpha-blockers, calcium channel blockers, renin inhibitors, and vasodilators. Diuretics, also known as water pills, are medications that increase the amount of water and salt excreted by the body in the form of urine. The various sources of diseases include primary hypertension and secondary hypertension, which are treated in hospitals, clinics, and at home care. The anti-hypertensive drugs market research report is one of a series of new reports from The Business Research Company that provides anti-hypertensive drugs market statistics, including anti-hypertensive drugs industry global market size, regional shares, competitors with an anti-hypertensive drugs market share, detailed anti-hypertensive drugs market segments, market trends and opportunities, and any further data you may need to thrive in the anti-hypertensive drugs industry. This anti-hypertensive drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global anti-hypertensive drugs market size will grow from $37.65 billion in 2022 to $38.70 billion in 2023 at a compound annual growth rate (CAGR) of 2.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global anti-hypertensive drugs market size is expected to grow to $41.19 billion in 2027 at a CAGR of 1.6%. A sedentary lifestyle is a major driver of the growth of the anti-hypertensive drug market. Consumption of junk food, lack of proper healthy and balanced diet, and lack of proper sleep due to irregular work shifts have contributed to the increase in hypertension. Hypertension is the underlying factor for at least 45% of deaths due to heart disease and 51% of deaths due to stroke. Once the patient is diagnosed with hypertension, patients are required to use the drugs to control hypertension based on the severity of the condition. Furthermore, in June 2021, according to the World Health Organization data 2021, a Switzerland-based Government agency responsible for international public health, cardiovascular diseases (CVDs) are the leading cause of death globally, taking an estimated 17.9 million lives each year. This creates a sustainable demand for the product and acts as a prominent driver for the growth of the market. Low awareness of the antihypertensive drugs amongst the population is one of the major restraints in the anti-hypertensive drugs market. Firstly, most people in developing nations neglect their health checkups and are not aware of their existing hypertension condition in them until they detect extreme symptoms. Secondly, persons diagnosed with hypertension are not adherent to their medication schedule and stop taking medication after 1-2 weeks until symptoms return, thereby posing a huge challenge to the anti-hypertensive drugs market. For example, BMC Research notes published a research survey (from a developing country) which states that out of the total 112 hypertensive subjects with stroke, only 17% of them were adherent to antihypertensive medications. Lack of awareness and low drug adherence restraint the growth of the antihypertensive market. Of late, there has been a rise in the use of combination therapies compared to monotherapy treatment. Monotherapy is the treatment of hypertension with a single drug, while the use of combinations of drugs (Combination Therapy) allows for action on several different hypertensive mechanisms. When the two drugs are combined with different mechanisms of action, the effect is two to five times greater than monotherapy. Increasing the dose of monotherapy reduces coronary events by 29% and cerebrovascular events by 40%, while combining two antihypertensive agents with a different mechanism of action reduces coronary events by 40% and cerebrovascular events by 54%. Thus, the use of combination therapy provides greater protection to a target organ than increasing the dose of monotherapy. The trend of using combination therapy is thus more effective and is being widely accepted as well. The US Food and Drug Administration (FDA) issued guidance on developing fixed-combination drugs to treat hypertension. This primarily focuses on the clinical development of two-drug combinations of previously approved products. The US FDA expects to see a reduction in adverse effects for combinations that include doses below each drug’s maximum dose compared to single drug regimens at their maximum dose. Earlier physicians typically started a patient on a single drug and titrated up to a maximum dose before adding additional drugs to their program, current guidelines recommend starting patients on two drugs at less than their full doses. Hence, this guidance would keep a check on fixed-combination drugs. Major players in the anti-hypertensive drugs market are Merck & Co. Inc., Astra Zeneca PLC., Daiichi Sankyo Company Limited, Johnson & Johnson Ltd., Pfizer Inc., Novartis AG, Sanofi SA, United Therapeutics, Ranbaxy Laboratories, Bayer AG, Lupin Limited, Boehringer Engelheim GmbH, Sun Pharmaceuticals LLC, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Roche, Abbott, Gilead, Actelion, and Teva Pharmaceutical Industries Ltd. North America was the largest region in the anti-hypertensive drugs market in 2022. The Middle East is expected to be the largest growing region in the global anti-hypertensive drugs market during the forecast period. The regions covered in the global anti-hypertensive drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the anti-hypertensive drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA. The anti-hypertensive drugs market consists of sales of thiazide-type diuretics, beta-blocker metoprolol, olmesartan, and HCTZ. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global anti-hypertensive drugs market is segmented - 1) By Therapeutics: Diuretics, Angiotensin Receptor Blockers (ARBs), Angiotensin Converting Enzyme (ACE) Inhibitors, Beta Blockers, Alpha Blockers, Calcium Channel Blockers, Renin Inhibitors, Vasodilators 2) By Disease Source: Primary Hypertension, Secondary Hypertension 3) By End Users: Hospitals, Clinics, Homecare

Alzheimer’s diseas treatment refers to a medication designed and developed to treat Alzheimer's. This treatment, which targets the protein beta-amyloid and is an immunotherapy, aids in the reduction of amyloid plaques, which are brain lesions connected to Alzheimer's disease. The progression of this disease causes severe memory impairment and the person may lose the ability to carry out everyday tasks. The main types of drugs in alzheimer’s disease treatment are cholinesterase inhibitors and NMDA receptor antagonists. Cholinesterase inhibitors (also known as acetylcholinesterase inhibitors) are a class of drugs that prevent acetylcholine from being broken down normally. The different drug classes include cholinergic, memantine, combined drug, AChE inhibitors, and immunoglobulins and involve various therapeutics such as cholinesterase inhibitors, NMDA receptor antagonists, and other therapeutics. The alzheimer’s disease treatment market research report is one of a series of new reports from The Business Research Company that provides alzheimer’s disease treatment market statistics, including alzheimer’s disease treatment industry global market size, regional shares, competitors with an alzheimer’s disease treatment market share, detailed Alzheimer’s disease treatment market segments, market trends and opportunities, and any further data you may need to thrive in the Alzheimer’s disease treatment industry. This Alzheimer’s disease treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global alzheimer’s disease treatment market grew from $5.08 billion in 2022 to $5.48 billion in 2023 at a compound annual growth rate (CAGR) of 8.0%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The alzheimer’s disease treatment market is expected to grow from $7.37 billion in 2027 at a CAGR of 7.7%. The increasing cases of Alzheimer's are a major factor contributing to the growth of the Alzheimer's treatment market. Alzheimer's is the most common type of dementia. The USA Alzheimer's Association expects that all the states in the US are projected to face a rise of at least 14% in the number of Alzheimer’s patients by 2025 due to the increase in the geriatric population. At the global level, the estimated new cases of Alzheimer’s are expected to grow by 35% to 615,000 by 2030, and by 110% to 959,000 by 2050. Therefore, the increasing prevalence of Alzheimer’s disease is expected to drive the growth of the global Alzheimer’s disease treatment market. The lack of techniques for diagnosing Alzheimer’s disease (AD) is expected to limit the growth of the global Alzheimer’s disease treatment market. There is no definitive blood test, brain scan, or physical exam to diagnose AD, and so many conditions can produce symptoms like dementia, which is the primary clinical symptom of AD, making the diagnosis complicated. Due to the lack of a single test for diagnosis, specialists such as neurologists, neuropsychologists, geriatricians, and geriatric psychiatrists use a variety of approaches for diagnosis to confirm dementia, but it is still difficult to find the cause, resulting in late diagnosis. Lack of proper and quick diagnosis for AD hampers the market growth as it leads to a reduced number of diagnosed cases and thereby reduces the consumption of AD drugs. Increasing R&D investments and collaborations as a result of emerging treatment technologies is a key trend in the Alzheimer's disease (AD) treatment market.The Alzheimer's Association is assisting with funds to researchers in search of innovative therapeutic approaches and seeks more government funding for Alzheimer's studies. Technologies such as ß-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitors and anti-amyloid inhibitors are emerging in the AD market. For instance, Comentis and Astellas collaborated and entered the BACE inhibitor field with their peptidomimetic series. Manufacturing firms such as AC Immune, Adamas Pharmaceuticals, INmune Bio, Intra-Cellular Therapies, and vTv Therapeutics are focusing more on R&D investments with their research molecules in clinical trials to achieve a breakthrough in the treatment of Alzheimer's disease. In January 2020, Biogen Inc., a US-based multinational biotechnology company, acquired Pfizer Inc. for an upfront payment of $75 million with up to $635 million in potential additional development and commercialization milestone payments. Through this acquisition, Biogen plans to develop the Phase 1 asset for the treatment of Sundowning in Alzheimer’s disease (AD) and Irregular Sleep-Wake Rhythm Disorder (ISWRD) in Parkinson’s disease (PD). Pfizer Inc. is an American multinational pharmaceutical corporation engaged in the discovery, development, and manufacture of healthcare products, including medicines and vaccines. Major players in the alzheimer’s disease treatment market are Allergan, Eisai Co. Ltd., Novartis AG, Pfizer Inc., Merz Pharma, H. Lundbeck A/S Biogen, AstraZeneca, and F. Hoffmann-La Roche Ltd. North America is the largest region in the alzheimer’s disease treatment market in 2022. Middle East is expected to be the fastest growing region in the global alzheimer’s disease treatment market during the forecast period. The regions covered in the global Alzheimer’s disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa. The countries covered in the alzheimer’s disease treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The Alzheimer’s disease treatment market includes revenues earned by entities by temporarily improve symptoms of memory loss and problems with thinking and reasoning. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organisations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the chain or as part of other products. The global Alzheimer's disease treatment market is segmented - 1) By Drug Class: Cholinergic, Memantine, Combined Drug, AChE inhibitors, Immunoglobulins 2) By Drug Type: Cholinesterase Inhibitors, NMDA Receptor Antagonists 3) By Therapeutics: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Other Therapeutics

Microbiology diagnostics devices and equipment are a broad category covering all kinds of items used in microbiology laboratories and used to diagnose infectious diseases by examining pathogens. These devices and equipment included microscopes, slides, test tubes, Petri dishes, growth media (liquid and solid), inoculation loops, pipettes, and tips, incubators, autoclaves, and laminar flow hoods. Some pieces of equipment are permanent, like microscopes and hoods, while others are not, like pipette tips. The main types of microbiology diagnostic devices and equipment are laboratory instruments, and microbiology analyzers. Laboratory instruments are types of instruments such as incubators, gram stainers, bacterial colony counters, petri dish fillers, and automated culture systems that are needed for operations in the laboratories. The micro-biology analyzers involved are microbiology diagnostics instruments and microscopes. The reagents are pathogen-specific kits, and general reagents. The end-users involved are hospitals, diagnostic centres, customer lab service providers, academic institutes, and research institutes. The microbiology diagnostics devices and equipment market research report is one of a series of new reports from The Business Research Company that provides microbiology diagnostics devices and equipment market statistics, including microbiology diagnostics devices and equipment industry global market size, regional shares, competitors with a microbiology diagnostics devices and equipment market share, detailed microbiology diagnostics devices and equipment market segments, market trends and opportunities, and any further data you may need to thrive in the microbiology diagnostics devices and equipment industry. This microbiology diagnostics devices and equipment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry. The global microbiology diagnostic devices and equipment market size will grow from $3.94 billion in 2022 to $4.43 billion in 2023 at a compound annual growth rate (CAGR) of 12.3%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global microbiology diagnostic devices and equipment market size is expected to grow from $6.35 billion in 2027 at a CAGR of 9.4%. Increasing funding of public and private investments in medical devices is driving the growth of the microbiology diagnostic devices market. Increasing Investments indicate the rising confidence of various private and public players on microbiology diagnostic devices, thereby indicating a progressive increase and stimulating growth. For instance, according to MedTech news, a publisher of new related to medical technology, private equity industry invested $111.8 B (c.$ 151 B) in healthTech industry. Furthermore, globally 96 deals valued at $40.8 billion were completed in medTech vertical. The increasing investments in digital health technologies, artificial intelligence and non-invasive monitoring capability, delivery of gene therapy and regenerative medicines technologies, and customized 3D printing of medical devices are expected to drive the microbiology diagnostic devices market. Unfavourable regulatory scenarios are major restraints in the microbiology diagnosis devices market. In the US, section 510(k) of the Food, Drug, and Cosmetic Act states that every device manufacturer must register with FDA and notify their intent to market a medical device at least 90 days in advance. These pre-market notifications are considered to be lengthy, rigorous, and time-consuming processes for the approval of medical devices. If in case the submission fails due to some uncertainty, the company has to reperform all the tests and resubmit the premarket approval application. For instance, a 'Verticle Autoclave', a microbiology diagnostic device, complies with the strict international directives and standards such as the capacity of 80-120 litre autoclave chamber volume, low sensitivity loads, restrictions on temperature calibration, and a certificate from ISO17025 accreditation lab for temperature, pressure gauges & timer. Next-Generation Sequencing (NGS) technologies are increasing their prevalence in the microbiology diagnostic devices market due to their cost effectiveness, sensitivity to detect low-frequency variants, and comprehensive genomic coverage. Next-Generation Sequencing (NGS) or high throughput sequencing or Massively Parallel Sequencing (MPS) is a method of sequencing genomes with the ability to sequence hundreds to thousands of genes or gene regions and the capability to detect novel resistance genes (ARG) in bacteria. BioMérieux partnered with Illumina to develop bioMérieux EpiSe, an NGS service that will facilitate epidemiological monitoring of bacterial infections and monitor outbreaks in hospitals. Some of the modern next-generation sequencing technologies that help to sequence DNA and RNA include Illumina (Solexa) sequencing, Roche 454 sequencing, Ion torrent Proton / PGM sequencing, and SOLiD sequencing. On May 26th, 2022, The IVD Regulation seeks to ensure a high level of public health and patient safety taking into account scientific progress, and smooth operation of the single market for these products. These changes by the EU legislation aid in the development of microbiology diagnostic devices, as they focus on providing transparency of information through EUDAMED (the new European database of medical devices), allowing manufacturers to monitor products, stronger clinical evidence, post-market surveillance, and enhance safety improvements. In April 2022, DCN Dx, a US-based manufacturer and developer of point-of-use tests, acquired Biomed Diagnostics for an undisclosed amount. The acquisition would expand DCN Dx’s footprint in the vertical of point-of-use testing and sampling markets for both humans and animals.Biomed Diagnostics is a US-based microbiological testing company. Major players in the microbiology diagnostics devices and equipment market are Becton Dickinnson and Company, Biomerieux, Danaher, Thermo Fisher Scientific, Abbott Laboratories, Bio-Rad Laboratories Inc., Bruker Corporation, Neogen Corporation, Merck KGaA, and Charles River Laboratories International Inc. North America was the largest region in the microbiology diagnostics devices and equipment market in 2022. Asia-Pacific was the second largest region in the global microbiology diagnostic devices and equipment market. The regions covered in the global microbiology diagnostic devices and equipment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa. The countries covered in the microbiology diagnostics devices and equipment market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The microbiology diagnostic devices and equipment consists of sales of instruments such as incubators, autoclave sterilizers, anaerobic culture systems, blood culture systems, gram strainers, microscopes, mass spectrometers, molecular diagnostic instruments, reagents pathogen-specific kits, and general reagents for microbiology diagnostic. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global microbiology diagnostic devices and equipment market is segmented - 1) By Type: Laboratory Instruments, Microbiology Analysers 2) By End User: Hospitals, Diagnostic Centres, Customer Lab Service Providers, Academic Institutes, Research Institutes 3) By Laboratory Instruments: Incubators, Gram Stainers, Bacterial Colony Counters, Petri Dish Fillers, Automated Culture Systems 4) By Micro-Biology Analyzers: Microbiology Diagnostics Instruments, Microscopes 5) By Reagents: Pathogen-Specific Kits, General Reagents

Viral vectors refer to a tool made of a viral genome that has been converted into a plasmid-based technology, modified for safety by deleting several necessary genes, and the viral components have been separated. Whereas, Plasmid DNA refers to a tiny, circular DNA molecule that can be found in some bacteria and other tiny organisms. Physically distinct from chromosomal DNA, plasmids multiply on their own. The main types of products in viral vectors & plasmid DNA are plasmid DNA and viral vectors. A plasmid is a single-stranded, circular DNA molecule that is different from the chromosomal DNA of a cell. Plasmids are found organically in bacterial cells as well as in certain eukaryotes. Plasmid genes frequently confer genetic benefits to bacteria, such as antibiotic resistance. The different diseases include infectious diseases, genetic disorders, cancer, and others, and are used in gene and cancer therapies, viral infections, immunotherapy, formulation development, and others. The several sectors include research institutes, biopharmaceutical companies, and pharmaceutical companies. The viral vectors & plasmid DNA market research report is one of a series of new reports from The Business Research Company that provides viral vectors & plasmid DNA market statistics, including viral vectors & plasmid DNA industry global market size, regional shares, competitors with a viral vectors & plasmid DNA market share, detailed viral vectors & plasmid DNA market segments, market trends and opportunities, and any further data you may need to thrive in the viral vectors & plasmid DNA industry. This viral vectors & plasmid DNA market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry. The global viral vectors & plasmid dna market grew from $0.8 billion in 2022 to $0.91 billion in 2023 at a compound annual growth rate (CAGR) of 14.8%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The viral vectors & plasmid dna market is expected to grow from $1.47 billion in 2027 at a CAGR of 12.6%. The rise in the global incidence of cancer is driving the viral vector & plasmid DNA market. The major causes of most cancers include obesity, smoking, alcohol, and improper eating habits. According to the American cancer society 2020, an estimated 1.8 million new cancer cases diagnosed and 606,520 cancer deaths in the United States.Furthermore, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases.The rise in the global incidence of cancer is expected to boost the demand for the viral vectors and plasmid DNA market over the coming years. The unaffordable cost of gene therapies is a major challenge in the viral vectors & plasmid DNA market. The prices of gene therapies range from $0.2 million to $2.1 million. For instance, Gilead company's Yescarta is a gene therapy that costs around $0.3 million and Bluebird Bio's Letiglobin is another gene therapy costing around $2.1 million. The high price is due to various factors like government regulations, production costs, and so on. Therefore, the unaffordable cost of gene therapies is limiting the viral vector & plasmid DNA market growth. The companies in the viral vectors and plasmid DNA market are focusing on the launch of viral vector assays to boost gene therapy research. Viral vectors are tools commonly used by molecular biologists to deliver genetic material into cells and viral vector assays is an investigative procedure on viral vector. For example, in November 2022, PerkinElmer, an American testing laboratories company, announced the launch of its "ready-to-use" adeno-associated virus vectors (AAV) detection kits to support researchers working on gene therapies for a variety of diseases. The viral assays are designed to help researchers quickly and easily characterize viral vector particles being produced to enable decision-making for safe and efficient gene transfer. In January 2020, Cognate Bioservices Inc., a US-based company skilled in cell and cell-mediated gene therapy products, acquired Cobra Biologics, which specialised in providing manufacturing services for plasmid DNA and viral vectors, for an undisclosed amount. The acquisition is expected to create a platform for the life cycle management of cell and gene therapy products. Cobra biologics is well established in the development and manufacture of a variety of viral vectors and DNA. The combined Cognate and Cobra expertise is expected to push both the businesses to a better position to respond to current and future market demand. Major players in the viral vectors & plasmid DNA market are FUJIFILM Diosynth Biotechnologies, FinVector Vision Therapies, Lonza, Cobra Biologics and Pharmaceutical Services, Brammer Bio, ??n?k???r??r?t??n, Cell and Gene Therapy Catapult, VGXI and MassBiologics. North America is the largest region in the viral vectors and plasmid DNA market in 2022. The Middle East is expected to be the fastest growing region in the global viral vectors & plasmid DNA market. The regions covered in the global viral vectors & plasmid DNA market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the viral vectors & plasmid DNA market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA. The viral vectors and plasmid DNA market consists of sales of adeno-associated viral, adenoviral, lentiviral, and retroviral. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods. The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products. The global viral vectors and plasmid dna market is segmented - 1) By Product: Plasmid DNA, Viral Vectors 2) By Application: Gene And Cancer Therapies, Viral Infections, Immunotherapy, Formulation Development, Other Applications 3) By Disease: Infectious Diseases, Genetic Disorders, Cancer, Other Diseases 4) By End User: Research Institutes, Biopharmaceutical And Pharmaceutical Companies